Mark Hillman's GSK Position Overview
Mark Hillman (via Hillman Capital Management, Inc.) currently holds 97,432 shares of GSK plc (GSK) worth $5.38 M, representing 3.73% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Mark Hillman has maintained a strategic position in GSK, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 34,255 shares. Largest reduction occurred in Q1 2025, reducing 66,008 shares.
Analysis based on 13F filings available since 2013 Q2
Mark Hillman's GSK plc (GSK) Holding Value Over Time
Track share changes against reported price movement
Quarterly GSK plc (GSK) Trades by Mark Hillman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -16,904 | Reduce 14.78% | 97,432 | $55.19 |
| Q4 2025 | -27,443 | Reduce 19.36% | 114,336 | $49.04 |
| Q3 2025 | -10,820 | Reduce 7.09% | 141,779 | $43.16 |
| Q2 2025 | -12,544 | Reduce 7.60% | 152,599 | $38.40 |
| Q1 2025 | -66,008 | Reduce 28.56% | 165,143 | $38.74 |
| Q4 2024 | +34,255 | Add 17.40% | 231,151 | $33.82 |
| Q3 2024 | +1,770 | Add 0.91% | 196,896 | $40.88 |
| Q2 2024 | -38,360 | Reduce 16.43% | 195,126 | $38.50 |
| Q1 2024 | +100 | Add 0.04% | 233,486 | $42.87 |
| Q4 2023 | +522 | Add 0.22% | 233,386 | $37.06 |
| Q3 2023 | -1,817 | Reduce 0.77% | 232,864 | $36.25 |
| Q2 2023 | -2,735 | Reduce 1.15% | 234,681 | $35.64 |
| Q1 2023 | -463 | Reduce 0.19% | 237,416 | $35.58 |
| Q4 2022 | -6,099 | Reduce 2.50% | 237,879 | $35.14 |
| Q3 2022 | +243,978 | New Buy | 243,978 | $29.43 |
Mark Hillman's GSK plc Investment FAQs
Mark Hillman first purchased GSK plc (GSK) in Q3 2022, acquiring 243,978 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mark Hillman has held GSK plc (GSK) for 15 quarters since Q3 2022.
Mark Hillman's largest addition to GSK plc (GSK) was in Q3 2022, adding 243,978 shares worth $7.18 M.
According to the latest 13F filing for Q1 2026, Mark Hillman's firm, Hillman Capital Management, Inc., owns 97,432 shares of GSK plc (GSK), valued at approximately $5.38 M.
As of the Q1 2026 filing, GSK plc (GSK) represents approximately 3.73% of Mark Hillman's publicly disclosed stock portfolio, making it one of their key holdings.
Mark Hillman's peak holding in GSK plc (GSK) was 243,978 shares, as reported at the end of Q3 2022.